alexa Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase.


Journal of Hypertension: Open Access

Author(s): Anthony L Albiston, Sharon G McDowall, Duana Matsacos

Abstract Share this page

Central infusion of angiotensin IV or its more stable analogues facilitates memory retention and retrieval in normal animals and reverses amnesia induced by scopolamine or by bilateral perforant pathway lesions. These peptides bind with high affinity and specificity to a novel binding site designated the angiotensin AT4 receptor. Until now, the AT4 receptor has eluded molecular characterization. Here we identify the AT4 receptor, by protein purification and peptide sequencing, to be insulin-regulated aminopeptidase (IRAP). HEK 293T cells transfected with IRAP exhibit typical AT4receptor binding characteristics; the AT4 receptor ligands, angiotensin IV and LVV-hemorphin 7, compete for the binding of [125I]Nle1-angiotensin IV with IC50 values of 32 and 140 nM, respectively. The distribution of IRAP and its mRNA in the brain, determined by immunohistochemistry and hybridization histochemistry, parallels that of the AT4 receptor determined by radioligand binding. We also show that AT4 receptor ligands dose-dependently inhibit the catalytic activity of IRAP. We have therefore demonstrated that the AT4 receptor is IRAP and propose that AT4 receptor ligands may exert their effects by inhibiting the catalytic activity of IRAP thereby extending the half-life of its neuropeptide substrates.

  • To read the full article Visit
  • Subscription
This article was published in J BiolChem and referenced in Journal of Hypertension: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version